Product Licensing Deals In India Paying Off?
Executive Summary
India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.
You may also be interested in...
Asia Deal Watch: Oxford Biomedica’s First Japanese Partnership Focuses On Rare Retinal Disorder
Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.
Entresto Shines Brightly Among New Launches In India
Novartis’ Entresto has had a strong run in India, with two second brands in tow, while itraconazole and azilsartan therapies are among the other recent introductions that have gained traction in a competitive market.
Roche Primes New Push Via Cipla For Avastin, Actemra In India
Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the